Company Overview
| Stock Name | 康哲藥業控股有限公司 |
|---|---|
| Stock Code | 00867 |
| Company Full Name | 康哲藥業控股有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事營銷、推廣及銷售國內外專業制藥公司的處方藥品，另亦生產及銷售多個處方藥。 |
| Listing Date | 2010-09-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港北角英皇道510號港運大廈21樓2106室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.cms.net.cn |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 5.06 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 404,800,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 5.64 |
|---|---|
| First Day Open | HK$ 5.85 |
| First Day Change | 11.46% |
| First Day Volume | 211863000.0 |
| First Day Turnover | 1255170000.0 |
Use of Proceeds
| Use of Proceeds | 1、約8.3%或67.5百萬港元，將用于通過聘請更多合資格及專業員工及擴大醫院覆蓋范圍和地域范圍； 2、約12.5%或101.7百萬港元，將用于興建新培訓及會議中心以供進行醫生培訓、醫學會議及其他推廣活動以及員工培訓； 3、約8.3%或67.5百萬港元，將用于更換、改善或升級信息管理系統的軟硬件； 4、約33.3%或270.9百萬港元，將用于收購在中國推廣銷售藥品的獨家授權及尋求并購合適制藥公司的機會。 5、在取得理想的CMS024臨床進展后，約16.8%或136.7百萬港元，將用于興建一個生產廠房以供制造公司自行生產的藥品。 6、約10%或87.8百萬港元，將用于撥款向供應商采購進口藥品以滿足中國市場對我們的授權引進產品日益增加的需求； 7、約10%或81.3百萬港元，將用作我們的營運資金及其他一般企業用途； |
|---|
Underwriting Syndicate
Sole Sponsor (1)
UBS Securities Hong Kong Limited CE BIN466
Overall Coordinators (1)
UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (1)
UBS Securities Hong Kong Limited CE BIN466
Joint Lead Managers (1)
UBS Securities Hong Kong Limited CE BIN466
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 林剛 |
|---|---|
| Company Secretary | 吳三燕 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 林剛(46.39%) |
|---|
